Company Description
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Aug 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Dinesh Patel |
Contact Details
Address: 7707 Gateway Boulevard, Suite 140 Newark, California 94560 United States | |
| Phone | 510 474 0170 |
| Website | protagonist-inc.com |
Stock Details
| Ticker Symbol | PTGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001377121 |
| CUSIP Number | 74366E102 |
| ISIN Number | US74366E1029 |
| Employer ID | 98-0505495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dinesh V. Patel Ph.D. | Chief Executive Officer, President, Secretary and Director |
| Asif Ali | Executive Vice President and Chief Financial Officer |
| Dr. Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer |
| Mohammad Masjedizadeh Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Newman Yeilding M.D. | Executive Vice President, Chief Scientific Officer |
| Matthew M. Gosling J.D. | Executive Vice President and Chief Legal and Business Officer |
| Carena Spivey | Executive Vice President and Chief Human Resources Officer |
| Dr. Ashok Bhandari Ph.D. | Executive Vice President and Chief Discovery Officer |
| Carter J. King | Executive Vice President of Business Development |
| Abha Bommireddi | Executive Vice President and Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 10, 2026 | SCHEDULE 13G | Filing |
| Feb 6, 2026 | SCHEDULE 13G/A | Filing |
| Feb 6, 2026 | 144 | Filing |
| Jan 30, 2026 | SCHEDULE 13G/A | Filing |
| Jan 27, 2026 | 144 | Filing |